In vitro evaluation of the protective effects of 4-thujanol against mitomycin-C and cyclophosphamide-induced genotoxic damage in human peripheral lymphocytes.
4-Thujanol (sabinene hydrate), a bicyclic monoterpene alcohol, is found in the essential oils of many aromatic and medicinal plants and is widely used as a fragrance and flavouring agent in many different products. The aim of this study was to evaluate the protective effects of 4-thujanol against the genotoxic effects induced by mitomycin C (MMC) and cyclophosphamide (CP) in human lymphocytes, using the chromosome aberrations, sister chromatid exchanges, and micronucleus tests, in the absence and in the presence of S9 mix, respectively. The cells were treated with 0.25 µg/mL MMC and 28 µg/mL CP as alone and cotreated with 13 + 0.25, 26 + 0.25, and 52 + 0.25 µg/mL 4-thujanol + MMC and with 13 + 28, 26 + 28, and 52 + 28 µg/mL 4-thujanol + CP as a mixture. The present study showed that 4-thujanol was unable to reduce the genetic damage induced by MMC, in the absence of S9 mix. On the other hand, probably the metabolites of 4-thujanol act as an antagonist and markedly antagonize CP-induced genotoxicity, in the presence of S9 mix. In general, 4-thujanol + MMC and 4-thujanol + CP decreased the mitotic index, proliferation index and nuclear division index to the same extent or more than those of individual exposure of MMC or CP. In conclusion, 4-thujanol significantly reduced (p < 0.001) the genotoxic damage induced by CP but not MMC when compared with the respective positive control alone. We can suggest that 4-thujanol may improve the chemopreventive effects and may also reduce the harmful side effects of CP, which is widely used in chemotherapy against cancer, without reducing its antiproliferative activities.
Department of Biology, Mustafa Kemal University, Turkey. aysekocaman@gmail.com
Ayse Yavuz
AY
Kocaman
Erman Salih
ES
Istifli
Mehmet
M
Büyükleyla
Eyyüp
E
Rencüzogullari
Mehmet
M
Topaktaş
D016587:Antimutagenic Agents / Q000378:metabolism / Q000494:pharmacology*; D000081008:Bicyclic Monoterpenes; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002869:Chromosome Aberrations / Q000139:chemically induced; D003520:Cyclophosphamide / Q000378:metabolism / Q000633:toxicity*; D004247:DNA / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000473:pathology; D008297:Male; D048629:Micronuclei, Chromosome-Defective / Q000187:drug effects; D015162:Micronucleus Tests; D016685:Mitomycin / Q000378:metabolism / Q000633:toxicity*; D039821:Monoterpenes / Q000378:metabolism / Q000494:pharmacology*; D009153:Mutagens / Q000378:metabolism / Q000633:toxicity*; D000091243:Ribosomal Protein S9; D012269:Ribosomal Proteins / Q000378:metabolism; D055815:Young Adult
D016587:Antimutagenic Agents; D000081008:Bicyclic Monoterpenes; D039821:Monoterpenes; D009153:Mutagens; D000091243:Ribosomal Protein S9; D012269:Ribosomal Proteins; D016685:Mitomycin; D003520:Cyclophosphamide; D004247:DNA; C534325:2-methyl-5-(1-methylethyl)bicyclo(3.1.0)hexan-2-ol